Omeprazole-based Dual and Triple Regimens for *Helicobacter pylori*
Eradication in Children

Seiichi Kato, MD*; Junji Takeyama, MD*; Kyoko Ebina, MD*; and Hiroshi Naganuma, MD‡

**ABSTRACT.** Objective. To evaluate the efficacy and safety of omeprazole-based dual and triple regimens for the treatment of children with *Helicobacter pylori* infection.

Methods. Twenty-two patients (3 with gastric ulcer, 12 with duodenal ulcer, and 7 with nodular gastritis alone) were studied. Twelve ulcer patients also had nodular gastritis. The dual regimen included a 2-week course of omeprazole (0.6 mg/kg twice a day) and amoxicillin (30 mg/kg twice a day) (n = 10), and the triple regimen included the dual regimen plus clarithromycin (15 mg/kg twice a day) (n = 12). In patients with active ulcers, omeprazole once daily was administered for another 4 weeks. Endoscopic biopsies were taken before therapy and 4 weeks after completion of a 2-week course of therapy, and patients were followed for 6 months. The gastritis score (grade 0 to 3) and serum anti-*H pylori* IgG antibody titers were also determined.

Results. The regimens were tolerated by all patients. Eradication rates for the dual and triple regimens were 70% and 92%, respectively. Active ulcers completely healed within 6 weeks. Patients with nodular gastritis alone showed different clinical responses to therapy. Pre-treatment histology showed chronic gastritis in all patients. Successful *H pylori* eradication significantly reduced the mean gastritis score from 2.9 to 1.3, but unsuccessful eradication did not reduce it. The disappearance of antral nodularity often coincided with the success of eradication. Successful eradication significantly decreased pretreatment serum anti-*H pylori* IgG antibody titers by 29% at 1 month, by 52% at 3 months, and by 67% at 6 months. Side effects were mild and were reported in 23% of patients.

Conclusion. An omeprazole-based regimen is safe and may be a better option for eradication of *H pylori* in children. Antral nodularity is a macroscopic marker of *H pylori* infection. Pediatrics 1997;100(1). URL: http://www.pediatrics.org/cgi/content/full/100/1/e3; *Helicobacter pylori*, gastritis, omeprazole, amoxicillin, clarithromycin.

*Helicobacter pylori* infection is a major etiological factor in chronic gastritis and is highly associated with peptic ulcer disease. Eradication of *H pylori* dramatically reduces the recurrence rate of duodenal ulcer. Therefore, the aim of treatment for *H pylori*-associated peptic ulcer disease has changed from the mere suppression of gastric acidity to eradication of the organism. The National Institutes of Health recommended treatment with antimicrobial agents in addition to antisecretory drugs, regardless of whether recurrence occurs. In adults, high eradication rates (90% or higher) have been obtained with a traditional bismuth-based triple regimen that includes metronidazole and either amoxicillin or tetracycline. However, this regimen has disadvantages (such as complex administration and side effects) which lead to poor patient compliance in clinical practice. Metronidazole-resistant strains are also a problem. Recently, as an alternative to the traditional triple regimen, a simple omeprazole-based regimen has been introduced with a low incidence of side effects. This regimen has been most widely studied.

*H pylori* eradication with bismuth-based regimens has been also attempted in children with peptic ulcer disease or gastritis, However, there are few studies of omeprazole-based regimens. This study reports on the efficacy and safety of omeprazole-based dual and triple regimens in children with *H pylori*-associated gastroduodenal diseases.

**PATIENTS AND METHODS**

**Patients**

Between March 1995 and February 1996, 22 patients (age 8 to 16 years) were enrolled in this study (Table 1). Three patients had gastric ulcers, 12 had duodenal ulcers, and 7 had nodular gastritis with symptoms including epigastric pain, nausea, or vomiting. Nodular gastritis was also found in 12 of 15 patients with peptic ulcer disease. Among 10 patients with active ulcers, 2 received eradication therapy at the first presentation of the disease and 8 at recurrence. The clinical symptoms of these patients included hematemesis, epigastric pain, tarry stool, and/or anemia. At presentation, one patient with bleeding gastric ulcer and one with bleeding duodenal ulcer underwent endoscopic hemostasis with pure ethanol using a method reported previously. Five asymptomatic patients with a history of ulcer recurrence received eradication therapy for prevention of recurrence; the patients and their parents requested the therapy. None of the patients received either steroids or nonsteroidal antiinflammatory drugs. There was one smoker who was male and 16 years old. Informed consent was obtained from all patients and their parents before inclusion.

**Treatment and Follow-up**

Patients undergoing maintenance treatment with H2-receptor antagonists stopped the drugs at entry. In patients with active ulcers, eradication therapy was started after *H pylori* infection was confirmed by the rapid urease test (Stat-Urease, PML Microbiologicals, Canada). Drug dosage within each eradication regimen was based on the adult experience with high-dose regimens, including 20 mg omeprazole twice a day. The first 10 patients received the dual regimen: 0.6 mg/kg (maximum dose, 20 mg) omeprazole twice a day and 30 mg/kg (maximum dose, 1000 mg) amoxicillin twice a day at breakfast and at the evening meal for 14 days. The other 12 patients received the triple regimen: the dual...
regimen plus 15 mg/kg (maximum dose, 500 mg) clarithromycin twice a day for 14 days. In patients with active ulcers, once-daily omeprazole (0.6 mg/kg with a maximum dose of 20 mg) was administered for another 4 weeks. Patients without active ulcers or with nodular gastritis alone received only a 2-week course of eradication therapy.

Upper gastrointestinal endoscopy and biopsy were routinely performed before therapy and 4 weeks after completion of a 2-week course of treatment (at 6 weeks). Each patient was followed up for at least 6 months.

**H pylori Infection and Gastritis**

Two biopsy specimens were taken from the gastric antrum. The specimens were stained with hematoxylin-eosin and Giemsa for the histological investigation which included an *H pylori* test. Another two antral biopsies were examined for culture and urease activity of *H pylori*. The *H pylori* test was considered positive if at least one test (histology, culture or urease) gave a positive result. If all results were negative at 6 weeks, *H pylori* was considered to be eradicated. The antral biopsy specimens before and after eradication therapy were also studied for the degree of gastritis (Table 1). The degree of inflammation was graded according to Bazzoli et al.

- **Grade 0**, normal gastric histology; grade 1, slight increase in the number of mononuclear cells and neutrophils; grade 2, increase in the number of mononuclear cells; grade 3, increase in the number of mononuclear cells and neutrophils with epithelial invasion of neutrophils. The pathologist (H.N.) was unaware of the clinical course of the patients.

Serum IgG antibody against *H pylori* was measured using an enzyme immunoassay (Cobas Core Anti-*H pylori*-EIA, Nippon Roche, Japan) with a cutoff point of 6 U/mL. Blood samples were obtained before treatment and at 1, 3, and 6 months after treatment ended; they were frozen at −20°C. To avoid day-to-day and tube-to-tube variations, investigators collectively measured the samples with the same lots of the assay kit.

### Intragastric pH Monitoring

To evaluate acid suppression with omeprazole in six patients, intragastric acidity was monitored for 24 hours (model KR-5010 pH monitor, Kuraray Co., Ltd., Japan) on days 5 to 13 of eradication therapy. After calibration, the electrode was transnasally positioned in the middle body of the stomach under fluoroscopy. The data were transferred to a personal computer and analyzed with respect to mean intragastric pH and *H*⁺ activity.

### Safety Assessment

Drug tolerance was investigated by questioning patients and parents about possible side effects: altered taste, diarrhea, nausea/vomiting, abdominal pain, skin eruption, and neurological symptoms (such as headache and dizziness). Laboratory examinations (including hemoglobin levels, white blood cell counts, platelet counts, serum electrolyte levels, hepatic and renal function tests, and urinalysis) were performed during therapy and at follow-up. Serum gastrin levels were also measured in all patients.

### Statistics

The differences in age and sex ratio of patients, frequency of side effects, and eradication rates between dual and triple regimens were analyzed by Fisher’s exact test, and differences in the mean gastritis score and serum anti-*H pylori* IgG antibody titers before and after eradication therapy were analyzed by the paired *t* test. A value of *P* < .05 was considered significant. The values were presented as mean ± SEM.

### RESULTS

#### Eradication and Gastritis

The first endoscopy demonstrated antral nodularity in 19 patients, multiple erosions in 2, and no macroscopic lesions in 1 (Table 2). Pretreatment histology showed chronic gastritis in all patients (mean gastritis score, 2.9). In 14 patients (13 with the nodu-
larity and 1 with erosions but no nodularity), pre-
treatment histology demonstrated lymphoid follicles
predominantly in the lamina propria. No patient had
intestinal metaplasia.

Examinations of the second biopsy specimens
demonstrated that *H pylori* was eradicated in 7 of 10
patients (70%) with the dual regimen and 11 of 12
patients (92%) with the triple regimen (Tables 1 and
2). There was no difference in eradication rate be-
tween regimens (*P* = .19). In all 10 patients with
active ulcers, the symptoms ceased within several
days after the initiation of therapy and the ulcers
completely healed with a full 6-week course of
treatment. Antral nodularity disappeared in 6 of 15 pa-
tients with successful eradication (Table 2). Success-
ful eradication therapy significantly reduced the
mean gastritis score from 2.9 to 1.6 (*P* < .005), but
unsuccessful eradication did not reduce it (*P* = .50).
Lymphoid follicles were detected in 11 patients after
eradication therapy.

**Intragastric Acidity**

With the eradication therapy, the mean intragastric
pH was 4.7 ± 0.3 (range, 3.5 to 6.0) and the mean
intragastric H⁺ activity was 0.99 ± 0.29 mmol/L
(range, 0.04 to 2.06). The percentages of time at a pH
of 2 or more, at a pH of 3 or more, and at a pH of 4
or more were 96.9 ± 1.2%, 85.3 ± 3.8%, and 64.7 ± 8.3%,
respectively.

**Serum Anti-*H pylori* Antibody**

Two patients were excluded from this serological
study, because they were seronegative at entry. Of
the remaining 20 patients, the mean pretreatment
titer of anti-*H pylori* IgG antibody was 66.9 U/mL
(range, 7.8 to 567.9). In successfully treated patients,
the IgG antibody titer decreased by an average of
29% at 1 month (*P* < .001), by 52% at 3 months (*P* <
.001), and by 67% at 6 months (*P* < .001), compared
with the pretreatment titers (Fig 1). Two patients
became seronegative at 6 months. In contrast, the IgG
antibody titers remained at baseline levels in patients
with persistent *H pylori* infection. Two patients who
were excluded from this serological study continued
to be seronegative in the follow-up period.

**Safety and Follow-up**

Drug compliance was good in all patients. The
overall incidence of side effects was 23%; diarrhea
was recorded in one patient given the dual regimen,
and metallic taste, dry mouth, and/or diarrhea in
four patients given the triple regimen (Table 1). Be-
cause the side effects were mild, however, discontinu-
ation of treatment was not necessary. Laboratory
examinations showed no abnormalities during or af-
after therapy. Although serum gastrin levels were
greater than normal at 2 to 4 weeks after treatment
started, they normalized within 3 months.

In patients with nodular gastritis alone in whom *H
pylori* was eradicated, the symptoms disappeared in
two patients, improved in three, and persisted in two
at 6 months. One patient with unsuccessful therapy
continued to have epigastric pain. Some patients
took 3 to 6 months to confirm a symptomatic re-

![Fig. 1. Serum anti-*H pylori* IgG antibody titers. Posttreatment titers are expressed as percentages of pretreatment levels in suc-
cessfully treated (solid bars) and unsuccessfully treated (shaded bars) patients. *P* < .001.](http://www.pediatrics.org/cgi/content/full/100/1/e3)
only two of eight patients. The previously reported that an average of 0.6 mg/kg daily of omeprazole is appropriate in most children with H2-receptor antagonist-resistant acid-related diseases. The dose of omeprazole in this study is twice as high as the suggested dose, which is relatively high for children compared with 40 mg daily in adults. The pH study has shown that 1.2 mg/kg daily of omeprazole powerfully reduces intragastric acidity, although the reduction may be insufficient in some patients. Eradication rates do not differ between 20 mg and 40 mg twice daily of omeprazole. A dose more than 1.2 mg/kg daily of omeprazole might be unnecessary in children.

The current belief is that an eradication rate more than 90% is essential for an ideal regimen. Additionally, simplicity of drug administration, low doses of antibiotics and a low incidence of side effects are desirable. On these grounds, wide study of omeprazole-based triple regimens shows that eradication rates of around 90% have been achieved, although the two antibiotics prescribed are usually amoxicillin and clarithromycin or a nitromidazole. However, there are only a few reports describing a regimen consisting of omeprazole, amoxicillin, and clarithromycin. The advantage of this regimen is that the risk of nitromidazole resistance is excluded. This study showed a high eradication rate, which is consistent with the results of adult studies. Although there was no statistical difference between dual and triple regimens (this study was not randomized), it may be attributable to the small number of patients studied. We believe that an omeprazole-based regimen is safe and a better therapeutic option for children with H pylori-associated gastroduodenal ulcers. More recently, a one-week course of an omeprazole-based triple regimen has been reported to have an eradication rate greater than 90%. Drug compliance is an important factor in determining the success of eradication. In this sense, the duration as well as doses of regimens must be further investigated.

Chronic gastritis with H pylori infection has various endoscopic appearances, including macroscopically normal mucosa with histologically confirmed inflammation. Antral nodularity is frequently observed especially in children with H pylori gastritis. Furthermore, many children with H pylori-associated duodenal ulcer also have antral nodularity. As previously reported, the present study proved that curing H pylori infection reduces the degree of gastric inflammation especially with a reduced number of neutrophils. In addition, the disappearance of antral nodularity was often demonstrated with H pylori eradication. On the contrary, Ashorn et al have stressed that the nodularity does not resolve along with active gastritis and persistent nodularity does not indicate persistent H pylori infection. The lymphoid follicles with germinal centers demonstrated by histology are probably involved in the pathogenesis of nodularity; however, lymphoid follicles were detectable in some patients in whom the nodularity subsided as evidenced by endoscopy. Although the degree of gastritis is reduced with successful eradication, the inflammatory reaction does not completely disappear in the short-term period after H pylori is eradicated. Antral nodularity is a macroscopic marker of H pylori infection and its eradication.

There is controversy regarding whether H pylori infection is related to symptoms of gastritis/nonulcer dyspepsia. Our patients with nodular gastritis alone demonstrated different symptom responses to eradication therapy. It was difficult to estimate the response shortly after eradication therapy. The symptomatic efficacy of the bismuth-based regimen may be associated with other mechanisms of bismuth salts (such as cytoprotection) rather than H pylori eradication. The role of H pylori and its eradication in the symptomatic relief of gastritis/nonulcer dyspepsia remains unclear.

H pylori eradication significantly reduced serum anti-H pylori IgG antibody titers; however, many patients continued to be seropositive. It may take more than 6 months after treatment to become seronegative. A 20% reduction of the IgG antibody titers by 6 months suggests successful eradication therapy, whereas no reduction suggests persistent H pylori infection. On the other hand, one study showed a decrease of antibody titers in half of the children with persistent H pylori infection. Our data suggests that serial assay of serum anti-H pylori IgG antibody titers is useful in long-term monitoring of H pylori eradication. At present, however, evidence of eradication should be founded on biopsy-based tests performed at 4 weeks or more after the completion of eradication therapy. In the future, noninvasive urea breath tests may be routinely available in the monitoring of H pylori infection. All children with H pylori-associated peptic ulcer disease should be treated not only for the ulcer but also for the H pylori infection. It is possible that successful eradication means cure of peptic ulcer disease.

REFERENCES

Omeprazole-based Dual and Triple Regimens for Helicobacter pylori Eradication in Children
Seiichi Kato, Junji Takeyama, Kyoko Ebina and Hiroshi Naganuma
Pediatrics 1997;100;e3
DOI: 10.1542/peds.100.1.e3

Updated Information & Services
including high resolution figures, can be found at:
/content/100/1/e3.full.html

References
This article cites 23 articles, 3 of which can be accessed free at:
/content/100/1/e3.full.html#ref-list-1

Citations
This article has been cited by 2 HighWire-hosted articles:
/content/100/1/e3.full.html#related-urls

Subspecialty Collections
This article, along with others on similar topics, appears in the following collection(s):
Gastroenterology
/cgi/collection/gastroenterology_sub

Permissions & Licensing
Information about reproducing this article in parts (figures, tables) or in its entirety can be found online at:
/site/misc/Permissions.xhtml

Reprints
Information about ordering reprints can be found online:
/site/misc/reprints.xhtml
Omeprazole-based Dual and Triple Regimens for *Helicobacter pylori* Eradication in Children

Seiichi Kato, Junji Takeyama, Kyoko Ebina and Hiroshi Naganuma

*Pediatrics* 1997;100:e3
DOI: 10.1542/peds.100.1.e3

The online version of this article, along with updated information and services, is located on the World Wide Web at:
/content/100/1/e3.full.html